ASH regularly produces educational webinars, video series, and podcasts that feature presentations by experts in the field, cover current information on how to best diagnose and care for patients, and topical discussion on issues relevant to hematology. This content is free to stream on ASH On Demand.
Treating older adults with acute myeloid leukemia is complicated, as the risk-benefit analysis for intensive and non-intensive therapeutic approaches is shifted compared to that in younger adults, and treatment recommendations must align with patient goals of care, which are by definition individualized. ASH has developed clinical practice guidelines for treating newly diagnosed acute myeloid leukemia in older adults that are sensitive to these issues, with approaches defined for real-time conversations that occur between patient and provider. This webinar will highlight the guideline recommendations along with the underlying evidence and rationale for the recommendations. Educational Objectives: • Determine the value of intensive and non-intensive chemotherapy in older adults with AML • For less-intensive therapy approaches, compare the safety and efficacy of monotherapy and combination • Determine the role of transfusions in palliative care and hospice settings
ASH has developed clinical practice guidelines on the use of anticoagulation for prevention of venous thromboembolism in patients with COVID-19. This webinar will highlight the guideline recommendations along with the underlying evidence and rationale for the recommendations. Educational Objectives: • Review two case-based presentations on recommendations for the use of anticoagulation to prevent venous thromboembolism in acutely and critically ill patients with COVID-19 • Describe the current evidence, research needs, and ASH plans to update the systematic reviews and recommendations • Provide an opportunity for Q&A
Moderator: Adam Cuker, MD, MS, University of Pennsylvania
Robby Nieuwlaat, PhD, MSc McMaster University
Deborah Siegal, MD, MSc, University of Ottawa
Erik Klok, MD, PhD, Leiden University Medical Center
Individuals with sickle cell disease (SCD) are living longer in the United States; however, barriers to receiving quality, comprehensive care for SCD remain, resulting in health care disparities and inequities. COVID-19 has further disrupted care and increased these challenges and mortality. To address these challenges and others, the National Academies of Sciences, Engineering, and Medicine (NASEM) recently released a new report entitled Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action, which provides recommendations for improving health care for the approximately 100,000 people in the U.S. with SCD. This briefing will present an overview about • the current state of SCD during the pandemic; • a personal story of a young adult’s journey with the disease; • key findings and recommendations from the NASEM report on SCD; • and a presentation of proposed policy strategies. Join us to learn how you can help improve SCD care and outcomes.
Biree Andemariam, MD, Chief Medical Officer, Sickle Cell Disease Association of America, Inc., University of Connecticut Health
Kyle A. Smith, MS, Crescent Foundation
Kim Smith-Whitley, MD, Children’s Hospital of Philadelphia
Chancellor Donald, MD, Chair, American Society of Hematology Committee on Practice, Tulane University
Drs. Lachelle Weeks and Joseph Telfair will discuss the topic of implicit bias and healthy equity. Specifically, the speakers will address the grounding and operational definitions of implicit or unconscious bias, how unconscious bias and racism appear in hematology, and actionable recommendations going forward. This webinar is designed to elicit a conversation on this important topic.
Lachelle Weeks, MD, PhD, Dana Farber Cancer Institute
Joseph Telfair, DrPH, MPH, MSW, HonFRSPH, Georgia Southern University
This webinar is for all ASH members who would like to learn more about how to get involved in the Society’s advocacy efforts. Attendees will learn about the importance of advocating on behalf of the hematology field, how to be an effective advocate, and the ASH resources available to be a successful advocate.
Alan Rosmarin, MD, Deputy Editor, Hematology, UpToDate, Chair of the ASH Committee on Government Affairs
Erin Morton, Senior Vice President, CRD Associates, Interim Executive Director of the Coalition for Health Funding
Jonathan Hoggatt, PhD, Massachusetts General Hospital, Harvard Medical School, Member of the ASH Committee on Government Affairs
Drs. Julie Rivers and Jennifer Yui, current ASH Medical Educators Institute (MEI) participants, will discuss their capstone project which served as a culminating academic experience for the MEI program. Their projects focused on cutting-edge teaching techniques including the development of an outpatient pediatric hematology curriculum and the improvement and assessment of educational conferences in benign hematology. They will describe the challenges, lessons learned, and best practices they experienced during the design and implementation of their respective projects and share their journey through the program including the impact it had on their careers.
Julie Rivers, MD, MS, Seattle Children’s Hospital / University of Washington
This webinar will focus on how to plan, organize, and design an effective medical education curriculum. Dr. Leslie Ellis will demonstrate the different models and factors that influence curriculum development, various teaching methods, how to achieve curricular goals and objectives, and how to adequately assess and evaluate a curriculum. Dr. Ellis will also explore various curriculum designs in times when virtual and distance learning is a prominent method of teaching.
Leslie R. Ellis, MD, MSHPEd, FACP, Wake Forest Baptist Health Comprehensive Cancer Center
The United States Department of Health and Human Services, in partnership with the American Society of Hematology and SickleinAfrica, and with the participation of the World Health Organization, hosted a webinar on June 29, 2020 on strengthening SCD efforts during the COVID-19 pandemic and beyond.
In February 2020, global stakeholders came together at the World Bank Headquarters in Washington, DC to initiate the Global Coalition on SCD which aims to develop, organize, and implement a global multi-sectoral approach to combatting SCD. On June 29, the 90-minute webinar highlighted current knowledge on the impact of COVID-19 on health care systems and access to care for individuals living with SCD. The webinar also included a discussion on the next steps of the Coalition.
The following presentations have been developed by the individual speaker. Information shared does not necessarily reflect the views or positions of ASH.
Martha Liggett, Esq, Executive Director, American Society of Hematology
Dr. Julie Makani, Associate Professor and Head of the Department of Hematology and Blood Transfusion at Muhimbili University of Health and Allied Sciences
Dr. Alexis Thompson, Section Chief of Hematology in the Department of Pediatrics Northwestern University School of Medicine
Admiral Brett Giroir, MD, Assistant Secretary for Health, United States Department of Health and Human Services
Pr. Jean-Marie Dangou, Coordinator, Noncommunicable Diseases Management World Health Organization Regional Office for Africa
Bukky Bolarinwa, President Sickle Cell Aid Foundation
Dr. Kwaku Ohene-Frempong, President, Sickle Cell Foundation of Ghana, Programme coordinator, National Newborn Screening Programme for Sickle Cell Disease
Dr. Isaac Odame, Medical Director of the Global Sickle Cell Disease Network at the Centre for Global Child Health at The Hospital for Sick Children, Toronto
Dr. Charles Kiyaga, Director of Programs, Partnerships & Global Health, Uganda National Health Laboratory Services, Ministry of Health
Juliana Richardson, Senior Policy Advisor US Department of Health and Human Services
Facilitator: Andrew Zapfel, MPH International Programs Manager, American Society of Hematology
New evidence is emerging daily that COVID-19 isn’t just a respiratory disease; it is a blood disease. Data are emerging that COVID-19 infection can result in coagulopathy in severely ill patients, and there are reports of an increased risk of clinical and subclinical thrombosis in the setting of severe COVID-19 disease with multiple reports citing an increased incidence of thrombosis, especially venous thromboembolism.
The rapid onslaught of cases, the severity of critical illness and complications, and the desire to do something have resulted in a significant debate about the appropriate anticoagulant approach to preventing both macrovascular and microvascular thrombosis at a time when no data are available to inform decisions and guide clinical care.
The webinar presents crucial controversies in this area, using a case-based format to highlight these issues and discuss the known data and pros and cons of empiric treatments.
After the webinar, participants will be able to: • Debate the optimal intensity of anticoagulation for thromboprophylaxis in COVID-19 patients admitted to the wards. • Debate the optimal intensity of anticoagulation for thromboprophylaxis in COVID-19 patients admitted to the ICU. • Discuss the potential pros and cons of post-discharge thromboprophylaxis in COVID-19 patients.
Moderator: Jean Connors, MD (Brigham and Women's Hospital)
Lisa M. Baumann Kreuziger, MD, MS (Versiti, Medical College of Wisconsin)
The upcoming webinar will introduce medical educators to the field of systems-based hematology, which centers around optimizing care delivery for patients with blood disorders. Dr. Morton and Dr. Connell will review how systems-based hematology can be integrated into medical education curricula and the roles that trainees may play in improving health care delivery.
After the webinar, participants will be able to: • Provide an overview of systems-based hematology • Discuss the importance of incorporating a systems based hematology mindset as a medical educator • Provide examples, tools, and techniques used by systems-based hematologists to implement change and improve quality • Discuss how systems-based hematologists can use their influence as leaders to create and manage change
Colleen Morton, MD (Vanderbilt-Ingram Cancer Center)